Compare ProShares Ultra Semiconductors (USD) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Semiconductors vs Zoetis Inc — how do they compare? ProShares Ultra Semiconductors trades at $95.15, while Zoetis Inc trades at $75.76 (market cap $30.39B). The key difference: Zoetis Inc pays a 2.88% dividend while ProShares Ultra Semiconductors pays none, and ProShares Ultra Semiconductors is trading nearer its 52-week high, Zoetis Inc nearer its low. Which is the better fit depends on your goals.
| USD | ZTS | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $113.53 | $156.76 |
52-Week Low | $40.97 | $71.91 |
Market Cap | — | $30.39B |
Enterprise Value | — | $37.95B |
Dividend Yield | — | 2.88% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
USD stock shows strong bullish momentum with the current price at $93.83, up 5.08% over the past 24 hours. Technical indicators signal overall bullish sentiment with moving averages strongly positive and oscillators neutral. The company has announced a future dividend payment scheduled for June 2026. Recent trading activity indicates robust investor interest as the stock approaches key resistance levels.
The stock's technical strength suggests continued upward potential, though overbought RSI conditions warrant caution. Key resistance at $95 presents the next test for bullish momentum. Long-term prospects depend on forthcoming financial disclosures and business execution. Market sentiment appears favorable but requires confirmation through upcoming earnings performance.
Zoetis (ZTS) trades at $75.83, up 0.64% on the day, but near its 52-week low after recent pressure. The stock shows bearish technical signals with support at $71 and resistance at $76. Fundamentally, the company maintains strong profitability with a 27.69% net margin and 64.91% ROE, though Q2 2026 revenue missed estimates and full-year guidance was cut due to softer pet healthcare demand. Recent news includes an FDA emergency use authorization for a new treatment and a class action lawsuit deadline.
The outlook is mixed: valuation appears reasonable with a P/E of 12, and analyst consensus targets $94.90, implying upside. However, near-term headwinds from competitive pressures and legal risks warrant caution. Long-term investors may find value if execution improves, but volatility could persist amid demand challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
